Innovation in Community Oncology: Moving Faster, Close to Home

Innovation in community oncology is no longer a future-facing slogan. It is the operating reality for practices trying to preserve access, sustain independence, support overextended teams, and deliver complex cancer care close to home.

This was clear at the 2026 Community Oncology Alliance Community Oncology Conference, themed “Innovation in Practice.” The meeting offered practical applications of artificial intelligence (AI), health policy change, next-generation therapies, and payer engagement around new models of care.

Sessions focused on how advanced therapies are moving beyond academic medical centers; physicians explained how community practices are becoming access points as cellular therapies move into more real-world settings. Then, administrators described the financial and payer challenges that practices face when building CAR T programs.

These conversations matter, because CAR T and bispecific antibodies are not just new treatments. They are new care models. Community access requires expanded infusion capabilities, symptom monitoring, emergency protocols, payer alignment, pharmacy leadership, and team education. The opportunity is enormous. But this will depend on whether community practices can build the infrastructure to safely deliver advanced therapies where patients live.

AI was another theme. The session, “AI as a Practice Partner: Operational & Clinical Wins in Community Oncology” focused on how AI can streamline documentation, support clinical decisions, and improve efficiency. Tools such as ambient AI have become especially relevant. Reducing documentation burden is not a convenience; it is a workforce strategy. Every minute returned to the care team can be used for patients, care coordination, or clinical judgment.

Flatiron Health, Paradigm Health, and the FDA have revealed this evolving ecosystem: Flatiron published the VALID Framework, a peer-reviewed approach for evaluating the quality and reliability of oncology real-world data extracted by large language models and machine learning. Paradigm Health’s acquisition of Flatiron’s Clinical Research Business created an oncology research network reaching nearly 100 community oncology practices. In April, the FDA took steps toward real-time clinical trials, with Paradigm to share data signals.

For community oncology, these developments point to a larger truth: clinical research, real-world evidence, AI, and regulatory modernization are converging. Practices that invest in research infrastructure today may be better positioned to offer trials tomorrow, generate evidence from routine care, and ensure that innovation reflects the patients treated in community settings.

But innovation alone is not enough. Community oncology also must advocate.

Advocacy is how practices protect their ability to keep delivering care in their communities. It is how they push back on reimbursement pressure, administrative burden, prior authorization, step therapy, copay barriers, and other policies that threaten access. COA’s advocacy sessions reflected that reality, including discussions of federal policy priorities and hot topics such as out-of-pocket costs, copay assistance, and step therapy.

Innovation and advocacy belong together. A practice cannot offer complex therapies, clinical trials, or comprehensive supportive care if payment and regulatory policy or payer barriers make those services unsustainable.

The final ingredient is connection. Community oncology thrives when practices share ideas, compare workflows, build partnerships, and learn from one another. Great ideas come from hallway conversations, peer-to-peer problem solving, and relationships that last beyond the conference.

The charge is clear: innovate boldly, advocate consistently, connect intentionally, with new ideas, new relationships, and renewed energy to move community oncology forward.